Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of TachoSil on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer

Trial Profile

Effect of TachoSil on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fibrinogen/thrombin (Primary)
  • Indications Bladder cancer; Prostate cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 15 May 2018 Results (n=100) assessing whether TachoSil(R), a hemostatic patch, can reduce the incidence of lymphocele formation in patients with prostate cancer, were published in the Urology.
    • 24 Aug 2017 Status changed from recruiting to completed.
    • 08 Apr 2016 Planned End Date changed from 1 Oct 2015 to 1 Oct 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top